Amphastar Pharmaceuticals, Inc. Total Long-Term Debt
Amphastar Pharmaceuticals, Inc. (AMPH) had Total Long-Term Debt of $40.30 million as of 2015-12-31, per its 10-K filed 2016-03-15.
Discontinued › Balance Sheet › Liabilities › Debt
us-gaap:LongTermDebt · last filed 2016-03-15
- 2015-12-31: Long-term Debt $40.30M.
- 2014-12-31: Long-term Debt $42.68M.
| Period end | Long-term Debt |
|---|---|
| 2015-12-31 | $40.30M 10-K · filed 2016-03-15 |
| 2014-12-31 | $42.68M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |